scholarly article | Q13442814 |
P2093 | author name string | Oystein Bruserud | |
Elisabeth Ersvaer | |||
Håkon Reikvam | |||
Kimberley J Hatfield | |||
P2860 | cites work | Physical interaction of Delta1, Jagged1, and Jagged2 with Notch1 and Notch3 receptors | Q24290323 |
The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells | Q24290490 | ||
TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms | Q24320364 | ||
Molecular genetic characterization of six recessive viable alleles of the mouse agouti locus | Q24533165 | ||
Binding of Delta1, Jagged1, and Jagged2 to Notch2 rapidly induces cleavage, nuclear translocation, and hyperphosphorylation of Notch2 | Q24550771 | ||
Direct inhibition of the NOTCH transcription factor complex | Q24634015 | ||
Therapeutic antibody targeting of individual Notch receptors | Q27660544 | ||
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement | Q27861120 | ||
Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration | Q28238880 | ||
A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice | Q43457473 | ||
Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism | Q43607424 | ||
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics | Q44077298 | ||
Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes | Q44625248 | ||
Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation | Q44746492 | ||
Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. | Q45154679 | ||
Notch2 integrates signaling by the transcription factors RBP-J and CREB1 to promote T cell cytotoxicity. | Q45345853 | ||
Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells | Q45863413 | ||
Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation. | Q46823521 | ||
Hey2 acts upstream of Notch in hematopoietic stem cell specification in zebrafish embryos | Q47073951 | ||
Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells | Q47619638 | ||
Viral disease prevention after hematopoietic cell transplantation | Q47627052 | ||
Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. | Q51790047 | ||
Prognostically useful gene-expression profiles in acute myeloid leukemia. | Q51999490 | ||
Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. | Q52044336 | ||
Down-regulation of Notch-1 expression decreases PU.1-mediated myeloid differentiation signaling in acute myeloid leukemia. | Q52587062 | ||
Cutting edge: Plasmacytoid dendritic cells induce IL-10 production in T cells via the Delta-like-4/Notch axis. | Q52906696 | ||
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. | Q52933515 | ||
Regulation of mesenchymal stem cell activity by endothelial cells. | Q54424874 | ||
Expression analysis of Notch-related molecules in peripheral blood T helper cells of patients with rheumatoid arthritis. | Q54442995 | ||
NOTCH1 mutations are rare in acute myeloid leukemia. | Q54571392 | ||
Diverse effects of the Notch ligands Jagged1 and Delta1 on the growth and differentiation of primary acute myeloblastic leukemia cells. | Q54668113 | ||
Acute lymphoblastic leukaemia | Q56722375 | ||
Fungal infection prevention after hematopoietic cell transplantation | Q56970496 | ||
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma | Q60976795 | ||
Toll-Like Receptors 3 and 4 Are Expressed by Human Bone Marrow-Derived Mesenchymal Stem Cells and Can Inhibit Their T-Cell Modulatory Activity by Impairing Notch Signaling | Q61638150 | ||
Serrate1-induced notch signalling regulates the decision between immunity and tolerance made by peripheral CD4(+) T cells | Q73399528 | ||
Recovery of lymphocyte and dendritic cell subsets after autologous CD34+ cell transplantation | Q73934560 | ||
Notch-1 regulates NF-kappaB activity in hemopoietic progenitor cells | Q74601849 | ||
Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery | Q78151865 | ||
Itch genetically interacts with Notch1 in a mouse autoimmune disease model | Q79344563 | ||
Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression | Q79954750 | ||
Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome | Q80138570 | ||
Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3 | Q80465114 | ||
Notch3 inhibition in myelin-reactive T cells down-regulates protein kinase C theta and attenuates experimental autoimmune encephalomyelitis | Q80633672 | ||
Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance | Q81308407 | ||
JAGGED1 and delta1 differentially regulate the outcome of experimental autoimmune encephalomyelitis | Q81464305 | ||
Defects in Notch1 upregulation upon activation of T Cells from patients with systemic lupus erythematosus are related to lupus disease activity | Q81638108 | ||
Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells | Q81974229 | ||
Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease | Q82856669 | ||
Notch signaling in the immune system | Q82881379 | ||
Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation | Q83339301 | ||
Immunological reconstitution after hematopoietic cell transplantation - its relation to the contents of the graft | Q94696821 | ||
Targeted therapy in acute myeloid leukaemia: current status and future directions | Q94863269 | ||
Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21 | Q95814547 | ||
Regulation of T cell activation by Notch ligand, DLL4, promotes IL-17 production and Rorc activation | Q95816367 | ||
Non-canonical activation of Notch signaling/target genes in vertebrates. | Q37748565 | ||
Targeting Notch to target cancer stem cells. | Q37763414 | ||
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. | Q38343552 | ||
Perturbation of Ikaros isoform selection by MLV integration is a cooperative event in Notch(IC)-induced T cell leukemogenesis | Q38352939 | ||
Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation | Q38511921 | ||
Notch2 signaling is required for potent antitumor immunity in vivo. | Q39721274 | ||
Notch signaling maintains proliferation and survival of the HL60 human promyelocytic leukemia cell line and promotes the phosphorylation of the Rb protein | Q39739099 | ||
Thymic development beyond beta-selection requires phosphatidylinositol 3-kinase activation by CXCR4. | Q39758257 | ||
DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency | Q39815141 | ||
Notch signaling: a novel regulating differentiation mechanism of human umbilical cord blood-derived mesenchymal stem cells into insulin-producing cells in vitro. | Q39885789 | ||
Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes | Q39997530 | ||
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells | Q40162776 | ||
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells | Q40163161 | ||
Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. | Q40226175 | ||
CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors | Q40281359 | ||
Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells | Q40769746 | ||
Wnt signaling regulates hemopoiesis through stromal cells. | Q40794241 | ||
Jagged2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through notch signaling | Q42602502 | ||
Notch versus the proteasome: what is the target of gamma-secretase inhibitor-I? | Q42957812 | ||
Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. | Q43202086 | ||
Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche | Q28505006 | ||
RBPjkappa-dependent Notch function regulates Gata2 and is essential for the formation of intra-embryonic hematopoietic cells | Q28511728 | ||
ER71 acts downstream of BMP, Notch, and Wnt signaling in blood and vessel progenitor specification | Q28587231 | ||
A role for Wnt signalling in self-renewal of haematopoietic stem cells | Q28592213 | ||
Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia | Q28646247 | ||
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia | Q29614269 | ||
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells | Q29615006 | ||
Osteoblastic cells regulate the haematopoietic stem cell niche | Q29615007 | ||
Identification of the haematopoietic stem cell niche and control of the niche size | Q29615008 | ||
Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice | Q30165266 | ||
Cis-interactions between Notch and Delta generate mutually exclusive signalling states | Q30494896 | ||
Proteasome inhibition reduces donor-specific antibody levels | Q33383491 | ||
Aberrant expression of Notch signaling molecules in patients with immune thrombocytopenic purpura | Q33385380 | ||
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study | Q33395926 | ||
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors | Q33531734 | ||
Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution | Q33642298 | ||
Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies | Q33713476 | ||
Impact of interactions of cellular components of the bone marrow microenvironment on hematopoietic stem and progenitor cell function | Q33806045 | ||
Cortical neural precursors inhibit their own differentiation via N-cadherin maintenance of beta-catenin signaling. | Q33834694 | ||
Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells | Q33837223 | ||
Hemgn is a direct transcriptional target of HOXB4 and induces expansion of murine myeloid progenitor cells | Q34052587 | ||
Downstream targets of HOXB4 in a cell line model of primitive hematopoietic progenitor cells | Q34052591 | ||
Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors | Q34152009 | ||
Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain | Q34189079 | ||
Glycosylation regulates Notch signalling. | Q34271410 | ||
Hematopoiesis is severely altered in mice with an induced osteoblast deficiency | Q34290169 | ||
The nervous system and innate immunity: the neuropeptide connection | Q34420533 | ||
Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? | Q34452706 | ||
TGFbeta/BMP inhibits the bone marrow transformation capability of Hoxa9 by repressing its DNA-binding ability | Q34545421 | ||
NOTCH1 pathway activation is an early hallmark of SCL T leukemogenesis | Q34663148 | ||
Notch signaling and the bone marrow hematopoietic stem cell niche | Q34776145 | ||
Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells | Q34957840 | ||
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma | Q34958884 | ||
Notch regulates cytolytic effector function in CD8+ T cells. | Q35219642 | ||
Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation | Q36021089 | ||
Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future | Q36090218 | ||
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. | Q36141686 | ||
The bone marrow vascular niche: home of HSC differentiation and mobilization | Q36262585 | ||
Separation of Notch1 promoted lineage commitment and expansion/transformation in developing T cells | Q36369337 | ||
Use of systemic proteasome inhibition as an immune-modulating agent in disease | Q36754730 | ||
Autoimmunity following haematopoietic stem-cell transplantation | Q36797795 | ||
Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens | Q36831660 | ||
Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells | Q36843721 | ||
Jagged2 acts as a Delta-like Notch ligand during early hematopoietic cell fate decisions | Q36905544 | ||
Delta-like 4 is the essential, nonredundant ligand for Notch1 during thymic T cell lineage commitment. | Q36946535 | ||
Signaling pathways governing stem-cell fate | Q36959565 | ||
Immunomodulation by mesenchymal stem cells and clinical experience | Q36975987 | ||
Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells | Q37029646 | ||
Dimorphic effects of Notch signaling in bone homeostasis. | Q37165102 | ||
Chronic GVHD as an autoimmune disease | Q37173483 | ||
Notch signaling and diseases: an evolutionary journey from a simple beginning to complex outcomes. | Q37215630 | ||
Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. | Q37307638 | ||
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. | Q37338140 | ||
Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation | Q37339719 | ||
Transmission and expansion of HOXB4-induced leukemia in two immunosuppressed dogs: implications for a new canine leukemia model | Q37357517 | ||
The different faces of Notch in T-helper-cell differentiation | Q37376021 | ||
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. | Q37495206 | ||
Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation | Q37509139 | ||
Proteasome inhibition for antibody-mediated rejection | Q37577254 | ||
Complexity of CEBPA dysregulation in human acute myeloid leukemia | Q37586686 | ||
Notch signaling in the hematopoietic system | Q37594765 | ||
Acute graft-versus-host disease: new treatment strategies | Q37610714 | ||
c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation | Q37620912 | ||
Wnt signaling in hematopoiesis: crucial factors for self-renewal, proliferation, and cell fate decisions | Q37673086 | ||
Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia | Q37688185 | ||
Novel roles for Notch, Wnt and Hedgehog in hematopoesis derived from human pluripotent stem cells | Q37718709 | ||
The chemokine system in experimental and clinical hematology | Q37724710 | ||
CXCR4 in clinical hematology | Q37732036 | ||
P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
P6216 | copyright status | copyrighted | Q50423863 |
P304 | page(s) | 570796 | |
P577 | publication date | 2010-10-04 | |
P1433 | published in | Bone Marrow Research | Q26842195 |
P1476 | title | Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies | |
P478 | volume | 2011 |